The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration

The pharmacokinetics of recombinant human relaxin (rhRlx) after intravenous (iv) bolus administration and the absorption of rhRlx after intracervical or intravaginal administration were determined in nonpregnant women. The study was conducted in two parts. In part I, 25 women received 0.01 mg/kg rhRlx iv. After a minimum 7-day washout period, these women were dosed intracervically (n = 10) or intravaginally (n = 15) with 0.75 or 1.5 mg rhRlx, respectively, in 3% methylcellulose gel. Part II was a double-blind, randomized, three-way crossover study in 26 women. At 1-month intervals, each woman received one of three intravaginal treatments consisting of 0 (placebo), 1, or 6 mg rhRlx in 3% methylcellulose gel. The serum concentrations of relaxin following iv administration were described as the sum of three exponentials. The mean (+/- SD) initial, intermediate, and terminal half-lives were 0.09 +/- 0.04, 0.72 +/- 0.11, and 4.6 +/- 1.2 hr, respectively. Most of the area under the curve was associated with the intermediate half-life. The weight-normalized clearance was 170 +/- 50 mL/hr/kg. The observed peak concentration was 98 +/- 29 ng/mL, and the weight-normalized initial volume of distribution was 78 +/- 40 mL/kg, which is approximately equivalent to the serum volume. If central compartment elimination was assumed, the volume of distribution at steady state (Vss/W) was 280 +/- 100 mL/kg, which is approximately equivalent to extracellular fluid volume. Vss/W could be as large as 1300 +/- 400 mL/kg without this assumption.(ABSTRACT TRUNCATED AT 250 WORDS)

Effect of extra energy as fat or milk replacer solids in diets of young dairy calves on growth during cold weather

The effects of feeding two levels of supplemental fat and extra milk replacer solids on Holstein calves housed in hutches during the winter were investigated. Fifty calves (10 per treatment) were assigned to the following dietary treatments: 1) milk replacer (control) reconstituted to 12.5% DM fed at 10% of BW (adjusted weekly), 2) same as treatment 1 plus 113 g/d of supplemental fat, 3) milk replacer reconstituted to 15% DM and fed at 10% of BW (adjusted weekly), 4) same as treatment 1 plus 226 g/d of supplemental fat, and 5) milk replacer reconstituted to 15% DM fed at 14% of BW (adjusted weekly). Half the amount of milk replacer consumed during wk 4 was fed during wk 5, and calves were weaned to dry feed at 35 d of age. A pelleted starter was offered for ad libitum intake throughout the 42-d trial. Gains in BW were greater for calves fed 226 than 113 or 0 g/d of supplemental fat (d 3 to 28). Calves fed milk replacer reconstituted to 15% DM at 14% of BW had greater BW gains during d 3 to 28 than control. Starter consumption was similar between groups receiving 113 and 0 g/d of fat supplement but lower in the group fed 226 g/d. Extra milk replacer solids in diets increased fecal scores to levels greater than those of calves in other groups. The benefit of fat supplementation of milk replacers was manifested as increased BW gain during the 1st mo of life.